Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 15.59 as of Sunday, July 26, 2026.
Forward PE Ratio (15.59) = Close Price ($202.19) / Consensus Forward EPS ($12.97)
FORWARD PE RATIO
15.59
SECTOR MEDIAN · HEALTHCARE
18.38
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
-15.20%
vs the sector median at left
Biogen Inc.
Market Cap
$29.85B
Forward PE Ratio
15.59
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Biogen Inc. (BIIB) | $29.85B | 15.59 |
| Centene Corp. (CNC)vs › | $31.31B | 18.05 |
| ResMed Inc. (RMD)vs › | $28.33B | 17.55 |
| Zoetis Inc. (ZTS)vs › | $31.59B | 10.95 |
| DexCom, Inc. (DXCM)vs › | $27.61B | 27.58 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $27.56B | 12.41 |
| Medline Inc. (MDLN)vs › | $32.77B | 25.58 |
| Mettler-Toledo International Inc. (MTD)vs › | $26.82B | 28.44 |
| Quest Diagnostics Incorporated (DGX)vs › | $25.15B | 20.67 |
| IQVIA Holdings Inc. (IQV)vs › | $34.72B | 16.24 |
Trailing P/E
21.6
reported TTM EPS
Forward P/E
15.6
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $12.97 implies +38.9% EPS growth vs the reported trailing $9.34.
At today's $202.19 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $12.97 | $-11.94 – $17.67 | 17 | 15.6x |
| 2027-12-31 | $16.31 | $12.15 – $19.79 | 19 | 12.4x |
| 2028-12-31 | $18.34 | $15.43 – $21.70 | 6 | 11.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
